1. Hicks, M.R. and A.D. Pyle, The emergence of the stem cell niche. Trends Cell Biol, 2023. 33(2): p. 112-123.
2. Slack, J.M.W., What is a Stem Cell?, in The Science of Stem Cells. 2017. p. 1-11.
3. Zare, M., et al., A Novel Protocol to Differentiate Induced Pluripotent Stem Cells by Neuronal microRNAs to Provide a Suitable Cellular Model. Chem Biol Drug Des, 2015. 86(2): p. 232-8.
4. Rasekhi, M., et al., A novel protocol to provide a suitable cardiac model from induced pluripotent stem cells. Biologicals, 2017. 50: p. 42-48.
5. Bakhshandeh, B., et al., Mechanotransduction in tissue engineering: Insights into the interaction of stem cells with biomechanical cues. Exp Cell Res, 2023. 431(2): p. 113766.
6. Poetsch, M.S., A. Strano, and K. Guan, Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine. Stem Cells, 2022. 40(6): p. 546-555.
7. Havasi, P., et al., Mesenchymal stem cells as an appropriate feeder layer for prolonged in vitro culture of human induced pluripotent stem cells. Mol Biol Rep, 2013. 40(4): p. 3023-31.
8. Hu, W. and M.A. Lazar, Modelling metabolic diseases and drug response using stem cells and organoids. Nat Rev Endocrinol, 2022. 18(12): p. 744-759.
9. Hoang, D.M., et al., Stem cell-based therapy for human diseases. Signal Transduct Target Ther, 2022. 7(1): p. 272.
10. Li, C., et al., Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice. Cell Biosci, 2021. 11(1): p. 187.
11. Zhang, Y., et al., Mesenchymal Stem Cells: Therapeutic Mechanisms for Stroke. Int J Mol Sci, 2022. 23(5): p. 2550.
12. Vahdat, S., et al., Expansion of Human Pluripotent Stem Cell-derived Early Cardiovascular Progenitor Cells by a Cocktail of Signaling Factors. Sci Rep, 2019. 9(1): p. 16006.
13. Meissner, T.B., H.S. Schulze, and S.M. Dale, Immune Editing: Overcoming Immune Barriers in Stem Cell Transplantation. Curr Stem Cell Rep, 2022. 8(4): p. 206-218.
14. Lamsfus-Calle, A., et al., Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches. Blood Rev, 2020. 40: p. 100641.
15. Lei, T., et al., Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps. Front Immunol, 2022. 13: p. 1031185.
16. Hara, H., et al., Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status. Immunology, 2013. 140(1): p. 39-46.
17. Buermann, A., et al., Pigs expressing the human inhibitory ligand PD-L1 (CD 274) provide a new source of xenogeneic cells and tissues with low immunogenic properties. Xenotransplantation, 2018. 25(5): p. e12387.
18. Martinez-Alarcon, L., et al., Profiling Human CD55 Transgene Performance Assist in Selecting Best Suited Specimens and Tissues for Swine Organ Xenotransplantation. Biology (Basel), 2021. 10(8): p. 747.
19. Kuwaki, K., et al., Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med, 2005. 11(1): p. 29-31.
20. Watanabe, H., et al., GalT-KO pig lungs are highly susceptible to acute vascular rejection in baboons, which may be mitigated by transgenic expression of hCD47 on porcine blood vessels. Xenotransplantation, 2018. 25(5): p. e12391.
21. Yan, J.J., et al., Role of Human CD200 Overexpression in Pig-to-Human Xenogeneic Immune Response Compared With Human CD47 Overexpression. Transplantation, 2018. 102(3): p. 406-416.
22. Rao, J.S., et al., HLA-G1(+) Expression in GGTA1KO Pigs Suppresses Human and Monkey Anti-Pig T, B and NK Cell Responses. Front Immunol, 2021. 12: p. 730545.
23. Rodríguez-Gago, M., et al., HUMAN ANTI-PORCINE γδ T-CELL XENOREACTIVITY IS INHIBITED BY HUMAN FasL EXPRESSION ON PORCINE ENDOTHELIAL CELLS1. Transplantation, 2001. 72(3): p. 503-509.
24. Wang, H.T., et al., Human CD31 on porcine cells suppress xenogeneic neutrophil-mediated cytotoxicity via the inhibition of NETosis. Xenotransplantation, 2018. 25(5): p. e12396.
25. Ahrens, H.E., et al., Kidneys From alpha1,3-Galactosyltransferase Knockout/Human Heme Oxygenase-1/Human A20 Transgenic Pigs Are Protected From Rejection During Ex Vivo Perfusion With Human Blood. Transplant Direct, 2015. 1(6): p. e23.
26. Niu, D., et al., Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science, 2017. 357(6357): p. 1303-1307.
27. Baptista, L.S., et al., 3D organ-on-a-chip: The convergence of microphysiological systems and organoids. Front Cell Dev Biol, 2022. 10: p. 1043117.
28. Cho, A.N., et al., Efficient Gene Expression in Human Stem Cell Derived-Cortical Organoids Using Adeno Associated Virus. Cells, 2022. 11(20): p. 3194.
29. Ren, X., et al., Patient-derived cancer organoids for drug screening: Basic technology and clinical application. J Gastroenterol Hepatol, 2022. 37(8): p. 1446-1454.
30. Watson, C.L., et al., An in vivo model of human small intestine using pluripotent stem cells. Nature medicine, 2014. 20(11): p. 1310-1314.
31. McLelland, B.T., et al., Transplanted hESC-derived retina organoid sheets differentiate, integrate, and improve visual function in retinal degenerate rats. Investigative ophthalmology & visual science, 2018. 59(6): p. 2586-2603.
32. Chen, Y.-W., et al., A three-dimensional model of human lung development and disease from pluripotent stem cells. Nature cell biology, 2017. 19(5): p. 542-549.
33. Wang, S.-N., et al., Cerebral organoids repair ischemic stroke brain injury. Translational Stroke Research, 2020. 11: p. 983-1000.
34. Tang, X.-Y., et al., Human organoids in basic research and clinical applications. Signal Transduction and Targeted Therapy, 2022. 7(1): p. 168.
35. Labusca, L., D.D. Herea, and K. Mashayekhi, Stem cells as delivery vehicles for regenerative medicine-challenges and perspectives. World J Stem Cells, 2018. 10(5): p. 43-56.
36. Li, M., et al., Potential pre-activation strategies for improving therapeutic efficacy of mesenchymal stem cells: current status and future prospects. Stem Cell Res Ther, 2022. 13(1): p. 146.
37. Almasi, R., Stem Cells and Their Therapeutic Applications for Human Diseases: A Review. J Stem Cell Rep, 2022. 4: p. 1-18.
38. Gao, Y., X. Yin, and X. Ren, Advance of Mesenchymal Stem Cells in Chronic End-Stage Liver Disease Control. Stem Cells Int, 2022. 2022: p. 1526217.
39. Salehi, M.S., et al., The Beneficial Potential of Genetically Modified Stem Cells in the Treatment of Stroke: a Review. Stem Cell Rev Rep, 2022. 18(2): p. 412-440.
40. Steinberg, G.K., et al., Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. Stroke, 2016. 47(7): p. 1817-24.
41. Chen, S., et al., Preconditioning and Engineering Strategies for Improving the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cell-Free Therapy. Stem Cells Int, 2022. 2022: p. 1779346.
42. Zhao, A.G., et al., Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Potential. Stem Cells Int, 2020. 2020: p. 8825771.
43. Wang, Y., et al., Rapid Delivery of Hsa-miR-590-3p Using Targeted Exosomes to Treat Acute Myocardial Infarction Through Regulation of the Cell Cycle. J Biomed Nanotechnol, 2018. 14(5): p. 968-977.
44. Chen, H., et al., Exosomes, a New Star for Targeted Delivery. Front Cell Dev Biol, 2021. 9: p. 751079.
45. Otani, K., et al., Nonviral delivery of siRNA into mesenchymal stem cells by a combination of ultrasound and microbubbles. Journal of Controlled Release, 2009. 133(2): p. 146-153.
46. Chen, Z., M. Du, and F. Yan, Recent Advances about Local Gene Delivery by Ultrasound, in Gene Expression and Control. 2018, IntechOpen.
47. Belling, J.N., et al., Acoustofluidic sonoporation for gene delivery to human hematopoietic stem and progenitor cells. Proceedings of the National Academy of Sciences, 2020. 117(20): p. 10976-10982.
48. Bez, M., et al., In situ bone tissue engineering via ultrasound-mediated gene delivery to endogenous progenitor cells in mini-pigs. Science translational medicine, 2017. 9(390): p. eaal3128.
49. Ruseska, I. and A. Zimmer, Internalization mechanisms of cell-penetrating peptides. Beilstein journal of nanotechnology, 2020. 11(1): p. 101-123.
50. Dixon, J.E., et al., Highly efficient delivery of functional cargoes by the synergistic effect of GAG binding motifs and cell-penetrating peptides. Proceedings of the National Academy of Sciences, 2016. 113(3): p. E291-E299.
51. Li, H., et al., Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal transduction and targeted therapy, 2020. 5(1): p. 1.
52. Zheng, N., L. Li, and X. Wang, Molecular mechanisms, off‐target activities, and clinical potentials of genome editing systems. Clinical and Translational Medicine, 2020. 10(1): p. 412-426.
53. Kim, H., et al., Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes. Laboratory animal research, 2018. 34(4): p. 147-159.
54. Kasatkina, L.A., et al., Optogenetic manipulation and photoacoustic imaging using a near-infrared transgenic mouse model. Nature communications, 2022. 13(1): p. 2813.
55. Zhang, H., et al., Systematic dissection of key factors governing recombination outcomes by GCE-SCRaMbLE. Nature Communications, 2022. 13(1): p. 5836.
56. Brunet, E., et al., Chromosomal translocations induced at specified loci in human stem cells. Proceedings of the National Academy of Sciences, 2009. 106(26): p. 10620-10625.
57. Walters, M.C., et al., Updated results of a phase 1/2 clinical study of zinc finger nuclease-mediated editing of BCL11A in autologous hematopoietic stem cells for transfusion-dependent beta thalassemia. Blood, 2021. 138: p. 3974.
58. Fleischer, A., et al., iPSC-derived intestinal organoids from cystic fibrosis patients acquire CFTR activity upon TALEN-mediated repair of the p. F508del mutation. Molecular Therapy-Methods & Clinical Development, 2020. 17: p. 858-870.
59. Choi, E.-B., et al., Transcription factor SOX15 regulates stem cell pluripotency and promotes neural fate during differentiation by activating the neurogenic gene Hes5. Journal of Biological Chemistry, 2023: p. 102996.
60. Madrigal, P., et al., Epigenetic and transcriptional regulations prime cell fate before division during human pluripotent stem cell differentiation. Nature Communications, 2023. 14(1): p. 405.
61. Urnov, F.D., et al., Genome editing with engineered zinc finger nucleases. Nature Reviews Genetics, 2010. 11(9): p. 636-646.
62. Guo, J., T. Gaj, and C.F. Barbas III, Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. Journal of molecular biology, 2010. 400(1): p. 96-107.
63. Singh, J.K., et al., Zinc finger protein ZNF384 is an adaptor of Ku to DNA during classical non-homologous end-joining. Nature communications, 2021. 12(1): p. 6560.
64. Chandrasegaran, S., Recent advances in the use of ZFN-mediated gene editing for human gene therapy. Cell Gene Ther Insights, 2017. 3(1): p. 33-41.
65. Kim, H. and J.-S. Kim, A guide to genome engineering with programmable nucleases. Nature Reviews Genetics, 2014. 15(5): p. 321-334.
66. Joung, J.K. and J.D. Sander, TALENs: a widely applicable technology for targeted genome editing. Nature reviews Molecular cell biology, 2013. 14(1): p. 49-55.
67. Li, T., et al., CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 2023. 8(1): p. 36.
68. Wang, N., et al., A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis. Nature Communications, 2023. 14(1): p. 779.
69. Xi, Z., et al., Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa. Nature Communications, 2022. 13(1): p. 7695.
70. Tabar, M.S., et al., Evaluating electroporation and lipofectamine approaches for transient and stable transgene expressions in human fibroblasts and embryonic stem cells. Cell Journal (Yakhteh), 2015. 17(3): p. 438.
71. Psatha, N., et al., In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations. Genes (Basel), 2022. 13(12): p. 2222.
72. Shinohara, T. and M. Kanatsu-Shinohara, Transgenesis and Genome Editing of Mouse Spermatogonial Stem Cells by Lentivirus Pseudotyped with Sendai Virus F Protein. Stem Cell Reports, 2020. 14(3): p. 447-461.
73. Abdul Halim, N.S., et al., A comparative study of non-viral gene delivery techniques to human adipose-derived mesenchymal stem cell. Int J Mol Sci, 2014. 15(9): p. 15044-60.
74. Nowakowski, A., et al., Genetic engineering of stem cells for enhanced therapy. Acta Neurobiol Exp (Wars), 2013. 73(1): p. 1-18.
75. Lim, J.Y., et al., Microporation is a valuable transfection method for efficient gene delivery into human umbilical cord blood-derived mesenchymal stem cells. BMC biotechnology, 2010. 10: p. 1-13.
76. Zhao, Z., A.C. Anselmo, and S. Mitragotri, Viral vector‐based gene therapies in the clinic. Bioengineering & translational medicine, 2022. 7(1): p. e10258.
77. Li, X., et al., Viral vector-based gene therapy. International Journal of Molecular Sciences, 2023. 24(9): p. 7736.
78. Li, L., et al., Virus integration and genome influence in approaches to stem cell based therapy for andro-urology. Advanced drug delivery reviews, 2015. 82: p. 12-21.
79. Paolini Sguazzi, G., et al., Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases. Int J Mol Sci, 2021. 22(24): p. 13674.
80. Li, C. and A. Lieber, Adenovirus vectors in hematopoietic stem cell genome editing. FEBS Lett, 2019. 593(24): p. 3623-3648.
81. Tinsley, R.B., et al., Improved non-viral transfection of glial and adult neural stem cell lines and of primary astrocytes by combining agents with complementary modes of action. J Gene Med, 2004. 6(9): p. 1023-32.
82. Rai, R., S. Alwani, and I. Badea, Polymeric Nanoparticles in Gene Therapy: New Avenues of Design and Optimization for Delivery Applications. Polymers (Basel), 2019. 11(4): p. 745.
83. Cui, S., et al., Correlation of the cytotoxic effects of cationic lipids with their headgroups. Toxicology Research, 2018. 7(3): p. 473-479.
84. Conrad, C., et al., Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther, 2007. 7(4): p. 249-60.
85. Ziraksaz, Z., et al., Evaluation of cationic dendrimer and lipid as transfection reagents of short RNAs for stem cell modification. Int J Pharm, 2013. 448(1): p. 231-8.
86. Bakhshandeh, B., et al., A comparative study on nonviral genetic modifications in cord blood and bone marrow mesenchymal stem cells. Cytotechnology, 2012. 64(5): p. 523-40.
87. Rejman, J., et al., mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J Control Release, 2010. 147(3): p. 385-91.
88. Di Gioia, S., et al., Cationic Polymers for Gene Delivery into Mesenchymal Stem Cells as a Novel Approach to Regenerative Medicine. Cationic Polymers in Regenerative Medicine. London: Royal Society of Chemistry, 2014: p. 386-437.
89. Corsi, K., et al., Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials, 2003. 24(7): p. 1255-64.
90. Hamann, A., A. Nguyen, and A.K. Pannier, Nucleic acid delivery to mesenchymal stem cells: a review of nonviral methods and applications. Journal of biological engineering, 2019. 13: p. 1-16.
91. Cao, F., et al., Comparison of gene-transfer efficiency in human embryonic stem cells. Molecular imaging and biology, 2010. 12: p. 15-24.
92. Agostini, F., et al., Nucleofection of Adipose Mesenchymal Stem/Stromal Cells: Improved Transfection Efficiency for GMP Grade Applications. Cells, 2021. 10(12): p. 3412.
93. Matsuoka, H., et al., High throughput easy microinjection with a single-cell manipulation supporting robot. J Biotechnol, 2005. 116(2): p. 185-94.
94. Zhang, Y. and L.-C. Yu, Microinjection as a tool of mechanical delivery. Current opinion in biotechnology, 2008. 19(5): p. 506-510.
95. Davis, B.R., et al., Glass needle–mediated microinjection of macromolecules and transgenes into primary human blood stem/progenitor cells. Blood, 2000. 95(2): p. 437-444.
96. Khalil, A.M., The genome editing revolution: review. J Genet Eng Biotechnol, 2020. 18(1): p. 68.
97. Danaeifar, M., Recent advances in gene therapy: genetic bullets to the root of the problem. Clin Exp Med, 2022.
98. Huang, X., et al., Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering. Cells, 2022. 11(14): p. 2186.
99. Bulcha, J.T., et al., Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther, 2021. 6(1): p. 53.
100. Nayerossadat, N., T. Maedeh, and P.A. Ali, Viral and nonviral delivery systems for gene delivery. Adv Biomed Res, 2012. 1: p. 27.
101. Gutierrez-Guerrero, A., F.L. Cosset, and E. Verhoeyen, Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy. Viruses, 2020. 12(9).
102. Mulia, G.E., et al., Advances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy. Hum Gene Ther, 2021. 32(19-20): p. 1076-1095.